Neumora Therapeutics has hit a road block to becoming a major neuroscience player, with the FDA placing a clinical hold on a Phase 1 study for one of its early-stage assets in schizophrenia.
The company said that the trial is on hold following “recently available” preclinical data for its drug dubbed NMRA-266 which showed convulsions in rabbits. Neumora said that 30 patients in the Phase 1 have already taken the drug, a modulator of the M4 muscarinic receptor, and no convulsions have been reported.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.